PAR 5.00% 19.0¢ paradigm biopharmaceuticals limited..

Ann: PAR Appoints Business Development Consultant, page-313

  1. 9,839 Posts.
    lightbulb Created with Sketch. 1258
    Yes AGM preso confirmed peer review was key deliverable for FY24:

    "OA manuscript following Day 56 & Day 168 PARA_OA_008 readout, detailing biomarker and clinical outcomes completed for peer review and publishing.
    • Manuscripts being completed to include significant data recently released detailing structural improvement by quantitative MRI analysis."
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.